| Information | |
|---|---|
| has gloss | eng: Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It was developed by Bristol-Myers Squibb. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed . |
| lexicalization | eng: BMS-477118 |
| lexicalization | eng: Saxagliptin |
| instance of | c/Drugs |
| Meaning | |
|---|---|
| Portuguese | |
| has gloss | por: Saxagliptina (BMS-477118) é um fármaco utilizado no tratamento do diabetes tipo 2. É um inibidor da enzima dipeptidil peptidase-4. |
| lexicalization | por: Saxagliptina |
| Media | |
|---|---|
| media:img | Production of saxagliptin.png |
Lexvo © 2008-2025 Gerard de Melo. Contact Legal Information / Imprint
